Royal Free Hospital and Division of Surgery and Interventional Science, UCL, United Kingdom.
Barts and the London School of Medicine, London, United Kingdom; St Bartholomew's Hospital, London, United Kingdom.
Breast. 2021 Feb;55:55-62. doi: 10.1016/j.breast.2020.11.023. Epub 2020 Dec 3.
The impact of neoadjuvant chemotherapy (NACT) on surgical outcomes following immediate breast reconstruction (IBR) remains unclear. While it is generally considered safe practice to perform an IBR post NACT, reported complication rates in published data are highly variable with the majority of studies including fewer than 50 patients in the NACT and IBR arm. To evaluate this further, we conducted a systematic review and meta-analysis on the effect of NACT on autologous and implant based immediate breast reconstructions. We aimed to assess for differences in the post-operative course following IBR between patients who received NACT with those who did not.
PubMed, EMBASE, and Cochrane Library were searched from 1995 to Sept 2, 2020 to identify articles that assessed the impact of NACT on IBR. All included studies assessed outcomes following IBR. Only studies comparing reconstructed patients receiving NACT to a control group of women who did not receive NACT were included. Unadjusted relative risk of outcomes between patients who received or did not receive NACT were synthesized using a fixed-effect meta-analysis. The evidence was assessed using the Newcastle Ottawa Scale scores and GRADE. Primary effect measures were risk ratios (RRs) with 95% confidence intervals.
A total 17 studies comprising 3249 patients were included in the meta-analyses. Overall, NACT did not increase the risk of complications after immediate breast reconstructions (risk ratio [RR]: 0.91, 95% CI 0.74 to 1.11, p = 0.34). There was a moderate, but not significant, increase in flap loss following NACT compared with controls (RR: 1.23, 95% CI 0.70 to 2.18, p = 0.47; I = 0%). Most notably, there was a statistically significant increase in implant/expander loss after NACT (RR: 1.54, 95% CI 1.04 to 2.29, p = 0.03; I = 34%). NACT was not shown to significantly increase the incidence of hematomas, seromas or wound complications, or result in a significant delay to commencing adjuvant therapy (RR: 1.59, 95% CI 0.66 to 3.87, p = 0.30).
Immediate breast reconstruction after NACT is a safe procedure with an acceptable post-operative complication profile. It may result in a slight increase in implant loss rates, but it does not delay commencing adjuvant therapy.
新辅助化疗(NACT)对即刻乳房重建(IBR)后手术结果的影响尚不清楚。虽然一般认为在 NACT 后进行 IBR 是安全的做法,但发表的数据中的报告并发症发生率差异很大,大多数研究中 NACT 和 IBR 臂的患者人数均少于 50 人。为了进一步评估这一点,我们对 NACT 对自体和植入物即刻乳房重建的影响进行了系统评价和荟萃分析。我们旨在评估接受 NACT 的患者与未接受 NACT 的患者在 IBR 后的术后过程是否存在差异。
从 1995 年至 2020 年 9 月 2 日,我们在 PubMed、EMBASE 和 Cochrane 图书馆中搜索评估 NACT 对 IBR 影响的文章。所有纳入的研究均评估了 IBR 后的结局。仅纳入比较接受 NACT 的重建患者和未接受 NACT 的对照组女性的研究。使用固定效应荟萃分析综合接受或未接受 NACT 的患者之间结局的未调整相对风险。使用纽卡斯尔-渥太华量表评分和 GRADE 评估证据。主要效应测量指标为风险比(RR)及其 95%置信区间。
共有 17 项研究,包括 3249 名患者,纳入荟萃分析。总体而言,NACT 并未增加即刻乳房重建后并发症的风险(RR:0.91,95%CI 0.74 至 1.11,p=0.34)。与对照组相比,NACT 后皮瓣丢失的风险适度增加,但无统计学意义(RR:1.23,95%CI 0.70 至 2.18,p=0.47;I²=0%)。值得注意的是,NACT 后植入物/扩张器丢失的风险显著增加(RR:1.54,95%CI 1.04 至 2.29,p=0.03;I²=34%)。NACT 并未显著增加血肿、血清肿或伤口并发症的发生率,也未导致辅助治疗开始时间明显延迟(RR:1.59,95%CI 0.66 至 3.87,p=0.30)。
NACT 后即刻乳房重建是一种安全的手术,术后并发症发生率可接受。它可能会导致植入物丢失率略有增加,但不会延迟辅助治疗的开始。